These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25472499)

  • 41. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
    Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
    Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
    Tan AR; Toppmeyer DL
    Clin Cancer Res; 2008 Nov; 14(21):6725-9. PubMed ID: 18980963
    [No Abstract]   [Full Text] [Related]  

  • 44. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Global experience with ixabepilone in breast cancer.
    Kaklamani VG; Xu BH; Gomez HL
    Expert Rev Anticancer Ther; 2011 May; 11(5):683-92. PubMed ID: 21554041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
    Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
    Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
    Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
    J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ixabepilone for the treatment of taxane-refractory breast cancer.
    Moulder SL
    Future Oncol; 2008 Jun; 4(3):333-40. PubMed ID: 18518758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.
    Alimonti A; Nardoni C; Papaldo P; Ferretti G; Caleno MP; Carlini P; Fabi A; Rasio D; Vecchione A; Cognetti F
    Anticancer Res; 2005; 25(5):3531-2. PubMed ID: 16101175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone.
    Harichand-Herdt S; O'regan RM
    Am J Clin Oncol; 2010 Dec; 33(6):561-7. PubMed ID: 20051810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
    Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative dosing schedules and administration updates for ixabepilone.
    Kossoff E
    J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
    Barnett CM
    Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
    Gonzalez-Angulo AM; Lei X; Alvarez RH; Green MC; Murray JL; Valero V; Koenig KB; Ibrahim NK; Litton JK; Nair L; Krishnamurthy S; Hortobagyi GN; Meric-Bernstam F
    Clin Breast Cancer; 2015 Oct; 15(5):325-31. PubMed ID: 25913905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.